Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an...

Area of Science:

• Neuro-oncology
• Molecular biology
• Nanomedicine

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis despite current treatments.
• Genetic mutations drive GBM progression, necessitating targeted genetic therapies.
• Small interfering RNA (siRNA) presents a promising tool for gene silencing in cancer treatment.

Purpose of the Study:

• To explore the potential of siRNA as a therapeutic agent for glioblastoma multiforme.
• To address the limitations of naked siRNA, such as degradation and off-targeting.
• To investigate the use of nanocarrier systems for enhanced siRNA delivery in GBM.

Main Methods:

• Gene silencing using siRNA targeting key GBM-related genes (e.g., VEGF, STAT3, EGFR).
• Development and evaluation of ligand-functionalized nanovehicles (e.g., CXCR4, angiopep-2) for siRNA delivery.
• Assessment of nanocarrier-mediated co-delivery of siRNA and anti-tumor drugs.

Main Results:

• siRNA demonstrates potential to down-regulate oncogenes and enhance chemosensitivity in GBM cells.
• Nanocarriers protect siRNA from enzymatic degradation and facilitate targeted delivery.
• Co-delivery systems offer a platform for combined gene silencing and chemotherapy.

Conclusions:

• siRNA-based therapies, particularly when delivered via advanced nanocarriers, hold significant promise for glioblastoma treatment.
• Nanotechnology-based delivery systems are crucial for overcoming the challenges associated with siRNA efficacy and safety.
• Further development of stable and biocompatible nanovehicles is essential for clinical translation of siRNA therapy for GBM.